Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 1/2017

01-01-2017 | Original Article—Alimentary Tract

Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats

Authors: Tsukasa Nozu, Saori Miyagishi, Rintaro Nozu, Kaoru Takakusaki, Toshikatsu Okumura

Published in: Journal of Gastroenterology | Issue 1/2017

Login to get access

Abstract

Background

Lipopolysaccharide (LPS) induces visceral hypersensitivity, and corticotropin-releasing factor (CRF) also modulates visceral sensation. Besides, LPS increases CRF immunoreactivity in rat colon, which raises the possibility of the existence of a link between LPS and the CRF system in modulating visceral sensation. The present study tried to clarify this possibility.

Methods

Visceral sensation was assessed by abdominal muscle contractions induced by colonic balloon distention, i.e., visceromotor response, electrophysiologically in conscious rats. The threshold of visceromotor response was measured before and after administration of drugs.

Results

LPS at a dose of 1 mg/kg subcutaneously (sc) decreased the threshold at 3 h after the administration. Intraperitoneal (ip) administration of anakinra (20 mg/kg), an interleukin-1 (IL-1) receptor antagonist, or interleukin-6 (IL-6) antibody (16.6 µg/kg) blocked this effect. Additionally, IL-1β (10 µg/kg, sc) or IL-6 (10 µg/kg, sc) induced visceral allodynia. Astressin (200 µg/kg, ip), a non-selective CRF receptor antagonist, abolished the effect of LPS, but astressin2-B (200 µg/kg, ip), a CRF receptor type 2 (CRF2) antagonist, did not alter it. Peripheral CRF receptor type 1 (CRF1) stimulation by cortagine (60 µg/kg, ip) exaggerated the effect of LPS, but activation of CRF2 by urocortin 2 (60 µg/kg, ip) abolished it.

Conclusions

LPS induced visceral allodynia possibly through stimulating IL-1 and IL-6 release. In addition, this effect was mediated through peripheral CRF signaling. Since the LPS–cytokine system is thought to contribute to altered visceral sensation in the patients with irritable bowel syndrome, these results may further suggest that CRF plays a crucial role in the pathophysiology of this disease.
Literature
1.
Taché Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep. 2009;11:270–7.CrossRefPubMed
2.
Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev. 2006;27:260–86.CrossRefPubMed
3.
Perrin MH, Vale WW. Corticotropin releasing factor receptors and their ligand family. Ann N Y Acad Sci. 1999;885:312–28.CrossRefPubMed
4.
Martínez V, Wang L, Million M, et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides. 2004;25:1733–44.CrossRefPubMed
5.
Fekete EM, Zorrilla EP. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol. 2007;28:1–27.CrossRefPubMed
6.
Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360:555–64.CrossRefPubMed
7.
Nozu T, Okumura T. Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome. J Gastroenterol. 2015;50:819–30.CrossRefPubMed
8.
Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun. 2011;25:386–94.CrossRefPubMed
9.
Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin N Am. 2005;34:235–45.CrossRef
10.
Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2012;46(Suppl):S52–5.CrossRefPubMed
11.
Moriez R, Salvador-Cartier C, Theodorou V, et al. Myosin light chain kinase is involved in lipopolysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol. 2005;167:1071–9.CrossRefPubMedPubMedCentral
12.
Dlugosz A, Nowak P, D’Amato M, et al. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 2015;27:1747–54.CrossRefPubMed
13.
Coelho AM, Fioramonti J, Bueno L. Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve. Am J Physiol Gastrointest Liver Physiol. 2000;279:G781–90.PubMed
14.
Benson S, Kattoor J, Wegner A, et al. Acute experimental endotoxemia induces visceral hypersensitivity and altered pain evaluation in healthy humans. Pain. 2012;153:794–9.CrossRefPubMed
15.
Yuan PQ, Wu SV, Wang L, et al. Corticotropin releasing factor in the rat colon: expression, localization and upregulation by endotoxin. Peptides. 2010;31:322–31.CrossRefPubMed
16.
Yuan PQ, Wu SV, Pothoulakis C, et al. Urocortins and CRF receptor type 2 variants in the male rat colon: gene expression and regulation by endotoxin and anti-inflammatory effect. Am J Physiol Gastrointest Liver Physiol. 2016;. doi:10.​1152/​ajpgi.​00337.​2015.
17.
Tsuchiya Y, Nozu T, Kumei S, et al. IL-1 receptor antagonist blocks the lipopolysaccharide-induced inhibition of gastric motility in freely moving conscious rats. Dig Dis Sci. 2012;57:2555–61.CrossRefPubMedPubMedCentral
18.
Nozu T, Takakusaki K, Okumura T. A balance theory of peripheral corticotropin-releasing factor receptor type 1 and type 2 signaling to induce colonic contractions and visceral hyperalgesia in rats. Endocrinology. 2014;155:4655–64.CrossRefPubMed
19.
Nozu T, Kumei S, Miyagishi S, et al. Colorectal distention induces acute and delayed visceral hypersensitivity: role of peripheral corticotropin-releasing factor and interleukin-1 in rats. J Gastroenterol. 2015;50:1153–61.CrossRefPubMed
20.
Tuna M, Erman T, Ildan F, et al. Effect of neutralization of rat IL-6 bioactivity on collateral blood supply from retrograde flow via cortical anastomoses in the rat central nervous system. Neurol Res. 2002;24:405–8.CrossRefPubMed
21.
Toth B, Yokoyama Y, Schwacha MG, et al. Insights into the role of interleukin-6 in the induction of hepatic injury after trauma-hemorrhagic shock. J Appl Physiol. 1985;2004(97):2184–9.
22.
Million M, Wang L, Wang Y, et al. CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats. Gut. 2006;55:172–81.CrossRefPubMedPubMedCentral
23.
Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat. Brain Res. 1988;450:153–69.CrossRefPubMed
24.
Okumura T, Nozu T, Kumei S, et al. Antinociceptive action against colonic distension by brain orexin in conscious rats. Brain Res. 2015;1598:12–7.CrossRefPubMed
25.
Nozu T, Miyagishi S, Nozu R, et al. Water avoidance stress induces visceral hyposensitivity through peripheral corticotropin releasing factor receptor type 2 and central dopamine D2 receptor in rats. Neurogastroenterol Motil. 2015. doi:10.​1111/​nmo.​12747.PubMed
26.
27.
Coelho A, Fioramonti J, Bueno L. Brain interleukin-1beta and tumor necrosis factor-alpha are involved in lipopolysaccharide-induced delayed rectal allodynia in awake rats. Brain Res Bull. 2000;52:223–8.CrossRefPubMed
28.
Obreja O, Rathee PK, Lips KS, et al. IL-1 beta potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C. FASEB J. 2002;16:1497–503.CrossRefPubMed
29.
Schafers M, Sorkin LS, Geis C, et al. Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neurosci Lett. 2003;347:179–82.CrossRefPubMed
30.
Leo M, Argalski S, Schafers M, et al. Modulation of voltage-gated sodium channels by activation of tumor necrosis factor receptor-1 and receptor-2 in small DRG neurons of rats. Mediat Inflamm. 2015. doi:10.​1155/​2015/​124942.
31.
Cunha TM, Verri WA Jr, Silva JS, et al. A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci. 2005;102:1755–60.CrossRefPubMedPubMedCentral
32.
Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797–819.CrossRefPubMed
33.
von Banchet GS, Kiehl M, Schaible HG. Acute and long-term effects of IL-6 on cultured dorsal root ganglion neurones from adult rat. J Neurochem. 2005;94:238–48.CrossRef
34.
Brenn D, Richter F, Schaible HG. Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain. Arthritis Rheum. 2007;56:351–9.CrossRefPubMed
35.
36.
Buckley MM, O’Halloran KD, Rae MG, et al. Modulation of enteric neurons by interleukin-6 and corticotropin-releasing factor contributes to visceral hypersensitivity and altered colonic motility in a rat model of irritable bowel syndrome. J Physiol. 2014;592:5235–50.CrossRefPubMedPubMedCentral
37.
Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: implications for cancer and cancer treatment. Brain Behav Immun. 2003;17(Suppl 1):S125–31.CrossRefPubMed
38.
Laye S, Parnet P, Goujon E, et al. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res Mol Brain Res. 1994;27:157–62.CrossRefPubMed
39.
Larauche M, Kiank C, Taché Y. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol. 2009;60(Suppl 7):33–46.PubMedPubMedCentral
40.
Gourcerol G, Wu SV, Yuan PQ, et al. Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents. Gastroenterology. 2011;140(1586–96):e6.
41.
Million M, Maillot C, Adelson DA, et al. Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats. Peptides. 2005;26:1188–95.CrossRefPubMed
42.
Yuan PQ, Wu SV, Taché Y. Urocortins and CRF type 2 receptor isoforms expression in the rat stomach are regulated by endotoxin: role in the modulation of delayed gastric emptying. Am J Physiol Gastrointest Liver Physiol. 2012;303:G20–31.CrossRefPubMedPubMedCentral
43.
O’malley D, Julio-Pieper M, Gibney SM, et al. Differential stress-induced alterations of colonic corticotropin-releasing factor receptors in the Wistar Kyoto rat. Neurogastroenterol Motil. 2010;22:301–11.CrossRefPubMed
44.
Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13:924–35.CrossRefPubMed
45.
Larauche M, Gourcerol G, Wang L, et al. Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways. Am J Physiol Gastrointest Liver Physiol. 2009;297:G215–27.CrossRefPubMedPubMedCentral
46.
Agelaki S, Tsatsanis C, Gravanis A, et al. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun. 2002;70:6068–74.CrossRefPubMedPubMedCentral
47.
Heinrichs SC, De Souza EB, Schulteis G, et al. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 2002;27:194–202.CrossRefPubMed
48.
Rorato R, Reis WL, de Carvalho Borges B, et al. Cannabinoid CB1 receptor restrains accentuated activity of hypothalamic corticotropin-releasing factor and brainstem tyrosine hydroxylase neurons in endotoxemia-induced hypophagia in rats. Neuropharmacology. 2012;63:154–60.CrossRefPubMed
49.
Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig. 2010;102:711–7.PubMed
50.
Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164–72.CrossRefPubMed
51.
Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–20.CrossRefPubMed
Metadata
Title
Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats
Authors
Tsukasa Nozu
Saori Miyagishi
Rintaro Nozu
Kaoru Takakusaki
Toshikatsu Okumura
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2017
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1208-y

Other articles of this Issue 1/2017

Journal of Gastroenterology 1/2017 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases

Original Article—Alimentary Tract

SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer

Editorial

Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B

Editorial

A novel intestinal organoid-based in vitro co-culture system to dissect out the initial host defense system

Editorial

Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir

Original Article—Alimentary Tract

A prospective, multicenter survey on the validity of shorter periendoscopic cessation of antithrombotic agents in Japan
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits